Gapping up
In reaction to earnings/guidance:
- CURV +16.2%, LULU +13.2%, LOVE +11%, RKLB +5.7% (also awarded multi-launch deal to deploy IoT satellite constellation for Kinéis), RH +2.3%, ASX +2.3% (Aug revs) SHCR +2.3%, HQY +1.2%, JILL +1%, .
Other news:
- CRDF +16% (announces Phase 1b/2 trial data showing robust objective response rate and progression free survival)
- CNTA +15.4% (reports topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B patients)
- PRQR +14.5% (announces licensing and research collaboration with LLY for Axiomer RNA editing)
- SIOX +5.3% (doses first GM1 Gangliosidosis early infantile patient in ongoing Phase 1/2 study of AXO-AAV-GM1 gene therapy)
- RKLY +3.6% (expands application of non-invasive biomarker sensing technology)
- BYSI +3.4% (Three Poster Presentations About its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress)
- CLSD +2.9% (to expand the territories covered by its exclusive license agreement with Arctic Vision)
- CHRA +2.6% (awarded 5-year fly ash sales and marketing contract for beneficial use of production fly ash at gavin power plant in Ohio)
- ZYNE +1.6% (presents data from the Phase 2 BRIGHT trial)
- NXU +1.5% (Energy Vault to accelerate global decarbonization, to list on the NYSE through merger with Novus Capital Corporation II)
- RIOT +1.2% (reports August production and operation updates)
- RYTM +1.2% (announces EAP for setmelanotide)
- TPTX +1.1% (to present abstract of early clinical data from TRIDENT-1)
- EVLO +1% (U.S. Patent and Trademark Office has issued a new composition of matter patent (No. 11,090,341) for medicines comprising pharmaceutical compositions of Veillonella parvula bacteria)
Analyst comments:
- APP +2.8% (upgraded to Buy from Hold at Stifel)
- BMRN +1.7% (upgraded to Buy from Hold at Stifel)
- M +0.9% (upgraded to Outperform from Market Perform at Cowen)